United States SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Amendment No. 1)
Under the Securities Exchange Act of 1934

AURIS MEDICAL HOLDING AG

(Name of Issuer)

Common Shares (Title of Class of Securities)

H03579101 (CUSIP Number)

December 31, 2015 (Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. H03579101

1.	Names of Reporting Persons							
	Bellevue Asset Management AG							
2.	· · · · · · · · · · · · · · · · · · ·							
	(a) \square (b) \square							
3.	. SEC Use Only							
4.	. Citizenship or Place of Organization							
	Switzerland							
		5.	Sole Voting Power					
Nu	mber of		0					
5	Shares reficially	6.	Shared Voting Power					
vO	vned by		0					
	Each porting	7.	Sole Dispositive Power					
I	Person with:		0					
	witti.	8.	Shared Dispositive Power					
			2,169,625					
9.	Aggrega	te A	mount Beneficially Owned by Each Reporting Person					
	2,169,625							
10.								
11.	Percent of Class Represented by amount in Row (9)							
	6.3%							
12.	. Type of Reporting Person (See Instructions)							
	IA							

۱	CI	IS	ΙP	N	า๋	H	U3	57	91	n	ľ

1.	1. Names of Reporting Persons								
	Oliver Kubli								
2.	2. Check the Appropriate Box if a Member of a Group (See Instructions)(a) □ (b) □								
3.	3. SEC Use Only								
4.	I. Citizenship or Place of Organization								
	Switzerland								
		5.	Sole Voting Power						
Number of			25,0001						
5	Shares	6.	Shared Voting Power						
Ov	neficially wned by		0						
Each Reporting		7.	Sole Dispositive Power						
F	Person with:		25,0001						
	witti.	8.	Shared Dispositive Power						
			2,169,625						
9.	Aggrega	ite A	amount Beneficially Owned by Each Reporting Person						
	2,194,6251								
10.	0. Check if the Aggregate Amount in Row (9) Excludes Certain Shares								
11.	Percent of Class Represented by amount in Row (9)								
	6.4%								
12.	12. Type of Reporting Person (See Instructions)								
	IN								

Includes 6,250 common shares of Auris Medical Holding AG that may be issued upon exercise of warrants held by Mr. Oliver Kubli.

Item 2

2(a) Name of Persons Filing:

This Schedule 13G is being filed by Bellevue Asset Management AG and Oliver Kubli. The common shares of Auris Medical Holding AG reported in this Schedule 13G as beneficially owned by Bellevue Asset Management AG (the "Adamant Shares") are held by BB Adamant Global Biotech, BB Adamant Global Generika, BB Adamant Global Medtech und Services, and Swisscanto (CH) Equity Fund Global Health Care (together, the "ZKB Funds"), each of which holds less than 5% of the common shares of shares in Auris Medical Holding AG. The ZKB Funds were previously known as, respectively, Adamant Global Biotech, Adamant Global Generika, Adamant Global Medtech und Services, and ZKB Fonds Aktien Gesundheit. The ZKB Funds are managed by Bellevue Asset Management AG, which exercises dispositive power over the Adamant Shares. The Adamant Shares are sponsored by Swisscanto Fondsleitung AG, Swisscanto Holding AG, and Zurcher Kantonalbank (together, the "Sponsors"), which exercise sole voting power over the Adamant Shares. Swisscanto Fondsleitung AG and Swisscanto Holding AG are successors by merger to, respectively, Balfidor Fondsleitung AG and Balfidor Holding AG. Mr. Kubli is a Senior Portfolio manager for the ZKB Funds. He disclaims beneficial ownership of the Adamant Shares except to the extent of his pecuniary interest therein. The Sponsors are unrelated to Bellevue Asset Management AG and Mr. Kubli.

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 2,194,6252
- (b) Percent of class: 6.4%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote <u>25,000</u>2
- (ii) Shared power to vote or to direct the vote $\underline{0}$
- (iii) Sole power to dispose or to direct the disposition of 25,0002
- (iv) Shared power to dispose or to direct the disposition of 2,194,6252

Includes 6,250 common shares of Auris Medical Holding AG that may be issued upon exercise of warrants held by Mr. Oliver Kubli.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bellevue Asset Management AG February 11, 2016 /s/ Cyrill Zimmerman **Signatory Authority** Cyrill Zimmerman Signatory Authority Date: _____ **February 11, 2016** /s/ Michael Hutter By: **Signatory Authority Michael Hutter** Name: **Signatory Authority** Title: __ Oliver Kubli Date: February 11, 2016 /s/ Oliver Kubli Oliver Kubli

Exhibit Index

Exhibit A: Agreement by and between Bellevue Asset Management AG and Oliver Kubli with respect to the filing of this disclosure statement.*

* Previously filed as an exhibit to Bellevue Asset Management AG and Oliver Kubli's Schedule 13G filed with the Securities Exchange Commission on May 14, 2015.